Antiretroviral treatment (ART) guidelines have changed over the past decade, recommending earlier initiation and more tolerable regimens. The study objective was to examine the CD4 response to ART, depending on the year of ART initiation, in HIV-positive patients in the Asia-Pacific. We included HIV-positive adult patients who initiated ART between 2003 and 2013 in our regional cohort from eight urban referral centres in seven countries within Asia. We used mixedeffects linear regression models to evaluate differences in CD4 response by year of ART initiation during 36 months of follow-up, adjusted a priori for other covariates. Overall, 16,962 patients were included. Patients initiating in 2006-9 and 2010-13 had an estimated mean CD4 cell count increase of 8 and 15 cells/ml, respectively, at any given time during the 36-month follow-up, compared to those in 2003-5. The median CD4 cell count at ART initiation also increased from 96 cells/ml in 2003-5 to 173 cells/ml in 2010-13. Our results suggest that the CD4 response to ART is modestly higher for those initiating ART in more recent years. Moreover, fewer patients are presenting with lower absolute CD4 cell counts over time. This is likely to reduce their risk of opportunistic infections and future non-AIDS defining cancers.
Introduction
CD4 cell counts are used as prognostic markers of HIV disease progression.
1,2 Untreated HIV-infected persons have a gradual depletion in CD4 cell levels, leading to increased risk of AIDS-defining illnesses and death. [3] [4] [5] [6] Combination antiretroviral therapy (ART) has been highly effective in preventing HIV disease progression and restoring CD4 cell levels as well as reducing viral replication and lowering rates of HIV-associated morbidity and mortality. or in asymptomatic stages with CD4 cell count <200 cells/ml. 10 Delayed ART initiation was earlier suggested in stable patients to reduce the risk of developing and transmitting drug-resistant HIV caused by suboptimal adherence. 11, 12 However, recent research has shown strong evidence to support that earlier ART initiation at higher CD4 cell levels is beneficial in preventing disease progression and transmission, and also prevents the incidence of opportunistic infections (OIs). 8, [13] [14] [15] Subsequent guideline revisions steadily increased the CD4 threshold for ART; in 2015, WHO treatment guidelines recommended ART initiation among all adults, regardless of CD4 cell count. 16 Other changes to the WHO treatment guidelines have also occurred over time, including the use of more tolerable and convenient ART regimens, increased support and counselling services for patients, and routine monitoring of CD4 cell count and HIV viral load. 16, 17 These changes have been accompanied by improvements in patient outcomes, with reduced mortality rates for patients receiving care in recent years. [18] [19] [20] Although part of these improvements has been attributed to earlier ART initiation at higher CD4 cell counts, year of ART initiation has also shown an independent association with improved overall survival. 21, 22 A greater CD4 cell count response has previously been associated with younger age, female gender, lower pre-ART HIV viral load and CD4 cell count. [23] [24] [25] Yet, there has been little exploration as to whether CD4 cell count response has improved in recent years of ART initiation. 23, 26 The changes to treatment guidelines and patient management over time could result in an improved CD4 cell count response for patients initiating ART in recent years. Specifically, the move towards newer ARV drugs, associated with fewer side effects, for patients receiving care in Asia could lead to greater patient adherence. 21 In addition, certain ARV drugs classes, such as protease inhibitor-based regimens, may also evoke an increased CD4 cell count response. [26] [27] [28] Our study objective was to examine the time trends in and factors associated with CD4 response to first-line ART, by calendar year of ART initiation, in HIV-positive patients receiving care in an Asian regional observational cohort study.
Methods

Data collection and participants
The TREAT Asia HIV Observational Database Low Intensity Transfer (TAHOD-LITE) cohort is a substudy of the TREAT Asia HIV Observational Database (TAHOD) and currently consists of eight sites from the Asia-Pacific region including Cambodia, Hong Kong, India, Indonesia, Singapore, South Korea and Vietnam. TAHOD collects detailed patient data on a subset of patients seen at 20 treatment sites in the Asia-Pacific region. 29 Conversely, TAHOD-LITE collects routine clinical data on all patients seen at the eight participating treatment sites. Thus, TAHOD-LITE is representative of the entire clinical population within our participating sites. Data are collected routinely when patients attend care at the treatment sites and include patient demographics, hepatitis serology, HIV-related laboratory test results and ART history. A more detailed description of TAHOD-LITE has been described elsewhere. 21 After being anonymized, data are transferred electronically to the Kirby Institute, UNSW Sydney and are subjected to quality control procedures. Data include patient follow-up until May 2014. TAHOD-LITE was granted ethical approvals from Institutional Review Boards (IRB) at each participating clinical site, UNSW Sydney and the coordinating centre at TREAT Asia/ amfAR. Written consent was not obtained unless required by the site-specific IRBs.
The data selected for this analysis included all patients who were aged over 18 years when they initiated an ART regimen, consisting of three or more drugs, between 1 January 2003 and 31 December 2013, and had at least one subsequent visit after the date of ART initiation. There were also site-based exclusions where patients were excluded if they had initiated ART prior to: 2006 for Singapore, 2010 for Vietnam and 2004 for Cambodia. Prior to these years, sites were unable to provide data on all patients that had been seen at the clinic.
Statistical analyses
The primary study objective was to evaluate CD4 cell count changes and factors associated with CD4 cell count change over 36 months of ART. A pseudo intention-to-treat approach was taken whereby any changes to treatment after ART initiation, including treatment interruptions, were ignored. All patients were censored at the last clinic visit or date of death or 36 months from ART initiation, whichever occurred earlier. Pre-ART laboratory measurements, including CD4 cell count and HIV viral load, were defined as those within six months prior, and closest to or on the date of ART initiation.
Data were modelled using repeated-measures, random-intercept linear regression using generalized least squares estimation to evaluate differences in the CD4 response between the year periods of ART initiation (2003-5, 2006-9, 2010-13) . Covariates, selected a priori, included clinical site, age at ART initiation, gender, mode of HIV exposure, pre-ART HIV viral load (copies/ml), pre-ART CD4 cell count (cells/ml), first ART regimen, hepatitis B and hepatitis C co-infection, time from ART initiation and squared time from ART initiation. These covariates were selected based on previous literature and available patient data collected in TAHOD-LITE. Continuous variables, including age at ART initiation, pre-ART HIV viral load and pre-ART CD4 cell count, were categorized in the model. First ART regimen was categorized based on the drug classes included. The squared time from ART initiation was included to allow for the predicted CD4 cell count to be modelled as a quadratic curve from ART initiation. We also evaluated whether there was an interaction between the year period of ART initiation and time from ART initiation in a sensitivity analysis. This model was selected for the analysis as it includes all CD4 cell count measurements during the 36 months of follow-up and determines whether certain factors influence the CD4 response over the entire follow-up time rather than at one time point (e.g. 12 months from ART initiation). As we modelled the CD4 cell count change from ART initiation, patients without a CD4 cell count result within six months prior to ART initiation (i.e. without a pre-ART CD4 cell count) were excluded from the model. CD4 cell count response was also summarized by the median CD4 cell count, with interquartile range (IQR), and the proportion of patients within each CD4 cell count category ( 50, 51-100, 101-200, 201-350, 351-500 and !501 cells/ml) every six months up to 36 months from ART initiation, by year of ART initiation, overall and for each country. For these crude summaries, we only included CD4 cell count measurements that were closest to and within AE3 months of the given time point.
Data were analysed using Stata version 12 (Stata Corporation, College Station, Texas, USA) and SAS (version 9.4 for Windows).
Results
A total of 18,441 patients aged over 18 years had initiated ART between 1 January 2003 and 31 December 2013. Of these, 777 patients were excluded for not attending the clinic after ART initiation and 702 patients were excluded due to site-based exclusions (see 'Methods' section; Singapore, n ¼ 70; Vietnam, n ¼ 568; Cambodia, n ¼ 64). The remaining 16,962 were included in the analysis.
Patient characteristics
A summary of the patient characteristics across all countries by year of ART initiation is given in Table 1 . Briefly, the majority of patients were male (Figure 1 ). Overall, there was an increasing trend where those initiating in 2010-13 had a higher median CD4 cell count at ART initiation follow-up compared to prior year periods. However, this was not found be significant in the Kruskal-Wallis median test (p value ¼ 0.368). Similar trends were observed when examined by country (Appendix 1).
The proportion of patients within each CD4 cell count category ( 50, 51-100, 101-200, 201-350, 351-500 and !501 cells/ml) up to 36 months from ART initiation is summarized in Figure 2 . Largely as a result of ART initiation at higher CD4 cell counts, there was an increasing trend where those initiating in 2010-13 had a greater proportion of patients at higher CD4 cell counts than in previous year periods. The proportion of patients with CD4 cell count ! 201 cells/ ml increased for patients initiating: in 2003-5, from 16% at ART initiation to 81% at 36 months; in 2006-9, from 25% at ART initiation to 85% at 36 months; and in 2010-13, from 44% at ART initiation to 85% at 36 months. This trend was also apparent by country (Appendix 2).
Modelling the CD4 cell count response up to 36 months
The model indicated that several factors were significantly associated with the CD4 cell count response over time (Table 2 ). In the univariate analysis, year period of ART initiation was significantly (p value < 0.001) associated with the CD4 cell response. Those initiating in 2006-9 and 2010-13 had a mean CD4 cell count that at any given time during follow-up was 8 cells/ml (95% CI: 3-13 cells/ml) and 13 cells/ml (95% CI: 8-19 cells/ml) higher than those initiating in 2003-5. In the multivariate model, the year period of ART initiation remained significant while adjusting for clinical site and other relevant covariates (p value < 0.001). Here, the mean CD4 cell count was higher at any given time during follow-up, for those initiating in 2006-9 and 2010-13 by 8 cells/ml (95% CI: 3-13 cells/ml) and 15 cells/ml (95% CI: 9-20 cells/ml), respectively, compared to those initiating in 2003-5. We conducted several sensitivity analyses to evaluate the robustness of our results. First, we evaluated whether there was an interaction between the year period of ART initiation and time from ART initiation. . Second, we evaluated whether the inclusion of pre-ART CD4 cell count in the model biased our estimated CD4 cell count change. Using a mixed-model approach with random intercept and random slope for time from ART initiation, we found minimal differences in the parameter estimates when pre-ART CD4 cell count was excluded (Appendix 4). We also found excluding other covariates with large proportions of missing data, such as pre-ART HIV viral load, HBV and HCV status, did not significantly affect the estimated mean CD4 cell count change for the covariates (Appendix 5). Third, we evaluated whether a mixed linear model with random intercept and random slope for time from ART initiation produced significantly different parameter estimates. The parameter estimates from this model were not substantially different from the primary analysis. The mean CD4 cell count difference was significantly higher, at any given time during follow-up, for those initiating in 2006-9 (p value ¼ 0.001) and 2010-13 (p value < 0.001) compared to those initiating in 2003-5 (Appendix 5).
Other factors in the multivariate model significantly associated with a higher CD4 cell count response, at any given time during follow-up, included younger age, female gender, homosexual contact (compared to heterosexual contact), higher pre-ART HIV viral load, lower pre-ART CD4 cell count, and HBV or HCV negative (compared to positive).
Discussion
In this analysis consisting of 16,962 HIV-positive patients receiving care in the Asia-Pacific region, our findings have shown that long-term CD4 response to ART is greater in those initiating in 2010-13 and 2006-9 compared to those initiating in 2003-5, regardless of CD4 cell count at ART initiation. There was an increasing trend with those initiating in more recent years having a greater CD4 response compared to previous years. Over the follow-up period, the median CD4 cell count was also consistently higher, and the proportion of patients with higher CD4 cell counts increased in more recent years.
Similar temporal trends in CD4 cell count at ART initiation have been shown in other studies. A large multiregional comparison of HIV-positive adults initiating ART between 2002 and 2009 found a steady increase in the median CD4 cell count at ART initiation in most countries. This trend was apparent regardless of the income status of the country, although the greatest increases were seen in low-and middleincome countries rather than in high-income countries and was also higher in females than males. 30 In contrast, a meta-analysis of 44 studies did not find a significant increasing trend in the mean CD4 cell count at presentation for newly presenting HIV-positive adults. The annual estimated change in CD4 cell count at presentation was 1.6 cells/ml (95% CI: À4.4 to 5.4 cells/ml) which was not significant (p > 0.05), adjusting for study inclusion criteria, data type and study location. 31 Overall, there were few studies that explored whether the year of ART initiation influenced the CD4 cell count response in HIV-positive patients. One study based in a London hospital showed an association between calendar year of ART initiation and CD4 response from ART initiation. 23 During the first three months of ART initiation, this association was not significant. However, beyond three months, patients initiating from 1997 to 2003 had a yearly CD4 cell count increase that was 84 cells/ml (95% CI: À48 to À120 cells/ml) higher than those initiating in 1996 and before.
It is also difficult to ascertain which factors of patient care have contributed to the improved CD4 cell count response in recent years. A move towards greater adherence in patients, either due to physician advice, support services, or more tolerable and convenient regimens, could have played an important role. 17, 32 Previous studies have highlighted that patients who are more adherent have greater and more sustained gains in CD4 cell count than non-adherent patients. [33] [34] [35] Other predictors significantly associated with improved CD4 cell count recovery are also consistent with former studies, including older age, female gender, pre-ART HIV viral load, HBV and HCV co-infection. [36] [37] [38] The clinical implications of our findings are fairly limited as those initiating in 2010-13 were only analysis has highlighted that the proportion of patients at high range CD4 cell counts has drastically increased over time, in particular, at ART initiation but also through to 36-month follow-up. Therefore, over time, fewer patients are being exposed to lower CD4 cell counts where they are at higher risk of OIs 39 and non-AIDS defining cancers (NADCs). 40, 41 Patients are also experiencing shorter durations at lower CD4 cell counts, which lead to a better overall prognosis. 42 An advantage of our study was the large patient sample size yet, our patient data were limited to a few variables. As such, we were unable to explore other important trends relating to lower CD4 cell counts, including the occurrence of NADCs or OIs. In addition, HIV viral load was not routinely collected at the clinical sites and had large proportions of missing data. Hence, we could not expand the scope of our analysis to also examine the HIV viral load response by year of ART initiation. Our model estimates for the pre-ART HIV viral load may also be bias and caution is advised when interpreting these findings.
We used observational data on CD4 cell counts collected during routine clinic visits for HIV-positive adults presenting between 2003 and 2013. Patients lost to followup (LTFU) can introduce potential bias that can impede on the analysis because it is unclear how many remain in care elsewhere or have died. The LTFU rate previously reported in TAHOD-LITE was relatively low and consistent between the years of ART initiation (2003-5: 2.1 per 100 person-years; 2006-9: 2.9 per 100 person-years; 2010-13: 2.8 per 100 person-years). 21 We also had eight clinical sites represent seven countries across the region, and hence, our results are reflective of trends occurring within the clinical sites rather than their respective countries. The presence of country-level differences in when patients present for care, available treatment options and patient care provided, as well as other unmeasured confounding factors could have also contributed to heterogeneity. However, our analysis by clinical site has shown similar trends to the overall analysis where there is an increasing trend in CD4 response over time by the year of ART initiation. Furthermore, the model used in our analysis is adjusted for clinical site to account for these differences between sites.
In summary, we found that the CD4 response to ART is greater in those initiating in 2010-13 and 2006-9 compared to those in 2003-5, with greater proportions of patients starting treatment at higher CD4 cell counts in recent years. Patients initiating in more recent years spend less time exposed in lower CD4 cell count ranges, reducing their risk for serious OIs and future NADCs that are associated with lower CD4 cell count. As guidelines recommending immediate ART are more widely implemented, it will be important to monitor their impact on immediate and long-term clinical outcomes.
